EDP Sciences logo
rechercher
Menu
Accueil Tous les numéros Numéro 23 (juillet 2021) Cah. Myol., 23 (2021) 12-17 References
Open Access
Issue
Cah. Myol.
Number 23, juillet 2021
Page(s) 12 - 17
Section Mise au point / Focus
DOI https://doi.org/10.1051/myolog/202123004
Published online 2 août 2021
  1. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 2021 ; 29 : 464–88. [CrossRef] [PubMed] [Google Scholar]
  2. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013 ; 24 : 59–67. [CrossRef] [PubMed] [Google Scholar]
  3. McGreevy JW, Hakim CH, McIntosh MA, et al. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech 2015 ; 8 : 195–213. [CrossRef] [PubMed] [Google Scholar]
  4. Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther 2018 ; 26 : 2337–56. [CrossRef] [PubMed] [Google Scholar]
  5. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002 ; 8 : 253–61. [CrossRef] [PubMed] [Google Scholar]
  6. Banks GB, Judge LM, Allen JM, et al. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 2010 ; 6 : e1000958. [CrossRef] [PubMed] [Google Scholar]
  7. Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics 2018 ; 15 : 840–8. [CrossRef] [PubMed] [Google Scholar]
  8. Le Guiner C, Servais L, Montus M, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun 2017 ; 8 : 16105. [CrossRef] [PubMed] [Google Scholar]
  9. Hayashita-Kinoh H, Guillermo PH, Nitahara-Kasahara Y, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev 2020 ; 20 : 122–41. [Google Scholar]
  10. Buscara L, Gross DA, Daniele N. Of rAAV et men: from genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back. J Pers Med 2020 ; 10 : 258. [CrossRef] [Google Scholar]
  11. Hakim CH, Wasala NB, Pan X, et al. A five-repeat microdystrophin gene ameliorated dystrophic phenotype in the severe dba/2j-mdx model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev 2017 ; 6 : 216–30. [CrossRef] [PubMed] [Google Scholar]
  12. Fortunato F, Rossi R, Falzarano MS, et al. Innovative therapeutic approaches for Duchenne muscular dystrophy. J Clin Med 2021 ; 10 : 820. [CrossRef] [PubMed] [Google Scholar]
  13. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of AAVrh74.MHCK7 micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol 2020 ; 77 : 1129–31. [Google Scholar]
  14. Pfizer’s new phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 studyPfizer - Communiqué de presse du 15 mai 2020. [Google Scholar]
  15. Luo S, Hu D, Wang M, et al. Complement in hemolysis- and thrombosis-related diseases. Front Immunol 2020 ; 11 : 1212. [CrossRef] [PubMed] [Google Scholar]
  16. Monteiro Pereira Palma L, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep 2021 ; 6 : 11–23. [CrossRef] [PubMed] [Google Scholar]
  17. Lemaire M, Noone D, Lapeyraque AL, et al. Inherited kidney complement diseases. Clin J Am Soc Nephrol 2021 ; 16 : 942–56. [CrossRef] [PubMed] [Google Scholar]
  18. Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr 2021 ; 231 : 265–8. [CrossRef] [PubMed] [Google Scholar]
  19. Li C, Goudy K, Hirsch, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci USA 2009 ; 106 : 10770–4. [CrossRef] [PubMed] [Google Scholar]
  20. George LA. No CpGs for AAVs? Blood 2021 ; 137 : 721–3. [CrossRef] [PubMed] [Google Scholar]
  21. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med 2010 ; 363 : 1429–37. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.